High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity

Analytical Biochemistry

Volumn 327, Issue 2, 2004, Pages 176-183

  Rowlands, Martin G ^a   Newbatt, Yvette M ^a   Prodromou, Chrisostomos ^a   Pearl, Laurence H ^a   Workman, Paul ^a   Aherne, Wynne ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

ATPase; Geldanamycin; Heat shock protein 90; High throughput screening; Malachite green; Phosphomolybdate

Indexed keywords

CARBONATE MINERALS; MOLYBDENUM COMPOUNDS;

ATPASE; GELDANAMYCIN; HEAT-SHOCK PROTEIN 90; HIGH THROUGHPUT SCREENING; MALACHITE GREEN; PHOSPHOMOLYBDATES;

PROTEINS;

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATASE INHIBITOR; BENZOQUINONE DERIVATIVE; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; MALACHITE GREEN; MOLYBDIC ACID; PHOSPHATE; RADICICOL; UNCLASSIFIED DRUG;

ARTICLE; CALORIMETRY; CHEMICAL REACTION KINETICS; COMPLEX FORMATION; DRUG IDENTIFICATION; DRUG SCREENING; ENZYME ACTIVITY; HIGH THROUGHPUT SCREENING; IC 50; PRIORITY JOURNAL;

SIPROETA STELENES;

EID: 1642503079     PISSN: 00032697     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ab.2003.10.038     Document Type: Article

References (46)

1. Maloney A., Workman P. Hsp90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin. Biol. Ther. 2:2002;3-24.
2. Neckers L. Hsp90 inhibitors as novel cancer therapeutic agents. Trends Mol. Med. 8:2002;555-561.
3. Issacs J.S., Wanping Xu, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell. 3:2003;213-217.
4. Prodromou C., Roe S.M., O'Brien R., Ladbury J.E., Piper P.W., Pearl L.H. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell. 90:1997;65-75.
5. Panaretou B., Prodromou C., Rose S.M., O'Brien R., Ladbury J.E., Piper P.W., Pearl L.H. ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO J. 17:1998;4829-4836.
6. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70.
7. Schulte T.W., Neckers L.M. The benzoquinone ansamycin 17-allylamino, 17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother. Pharmacol. 42:1998;273-279.
8. Supko J.G., Hickman R.L., Grever M.R. Malspeis, Preclinical pharmacologic evaluation of geldanamycin as an antitumour agent. Cancer Chemother. Pharmacol. 36:1995;305.
9. Deboer C., Meulman P.A., Wnuk R.J., Peterson D.H. Geldanamycin, a new antibiotic. J. Antibiot. (Tokyo). 23:1970;442.
10. Neckers L., Schulte T.W., Mimnaugh E. Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity. Invest. New Drugs. 17:1999;361-373.
11. Clarke P.A., Hostein I., Banerji U., Di Stefano F., Malony A., Walton M., Judson I., Workman P. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of the Hsp90 molecular chaperone. Oncogene. 19:2000;4125-4133.
12. Kelland L.R., Sharp S.Y., Rogers P.M., Myers T.G., Workman P. DT- diaphorase expression and tumour cell sensitivity to 17-allylamino, 17-demethoxygeldamycin, an inhibitor of heat shock protein 90. J. Natl. Cancer Inst. 91:1999;1940-1949.
13. Page J., Heath J., Fulton R., Yalkowsky E., Tabibi E., Tomaszewski J., Smith A., Rodman L. Comparison of geldanamycin (NSC-122570) and 17-allylaminogeldamycin (NSC-330507 D) toxicity in rats. Proc. Am. Assoc. Cancer Res. 38:1997;. Abs 308.
14. Wilson R.H., Takimoto C.H., Agnew E.B. Phase 1 pharmacologic study of 17-(allylamino) 17- demethoxygeldanamycin (AAG) in adult patients with advanced solid tumours. Proc. Am. Soc. Clin. Oncol. 20:2001;325.
15. Banerji U., O'Donnell A., Scurr M., Benson C., Hanwell J., Clark S., Raynaud F., Turner A., Walton M., Workman P., Judson I. Phase 1 trial of the heat shock protein 90 (HSP90) inhibitor 17-allylamino, 17-demethoxy- geldanamycin (17AAG). Pharmacokinetic (PK) profile and pharmacodynamic (PD) endpoints. Proc. Am. Soc. Clin. Oncol. 20:2001;326.
16. Banerjee U., Clarke P., Walton M., O'Donnell A., Raynaud F., Turner A., Judson I., Workman P. Preclinical and clinical activity of the molecular chaperone inhibitor 17-allylamino, 17-demethoxy-geldamycin(17AAG) in malignant melanoma. Proc. Am. Assoc. Cancer Res. 44:2003;. Abs 2966.
17. Erlichman C., Toft D., Reid J., Sloan J., Atherton P., Adjei A. A Phase 1 trial of 17-allyl-amino-geldanamycin in patients with advanced cancer. Proc. Am. Assoc. Cancer Res. 42:2001;4474.
18. Egorin M.J., Rosen D.M., Wolff J.H., Callery P.S., Musser S.M., Eiseman J.L. Metabolism of 17-(allylamino)-17- demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res. 58:1998;2385-2396.
19. Egorin M.J., Zuhowski E.G., Rosen D.M., Sentz D.L., Covey J.M., Eiseman J.L. Plasma pharmacokinetics and tissue distribution of 17(allylamino)-17- demethoxygeldanamycin (NSC 330507) in CD2F1 mice 1. Cancer Chemother. Pharmacol. 47:2001;291-293.
20. erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J. Med. Chem. 38:1995;3806-3812.
21. Schnur R.C., Corman M.L., Gallascun R.J., Cooper B.A., Dee M.F., Doty J.L., Muzzi M.L., DiOrio C.I., Barbacci E.G., Miller P.E., Pollack V.A., Savage D.M., Sloan D.E., Pustilnik L.R., Moyer J.D., Moyer M.P. erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action and structure-activity relationships. J. Med. Chem. 38:1995;3813-3820.
22. Maloney A., Walton M., Sharp S.Y., Kelland L.R., Jarman M., Prodromou C., Pearl L., Workman P. Structure-activity relationships of the Hsp90 inhibitor 17-allylamino 17-demethoxy geldanamycin analogues (17AAG). Clin. Cancer Res. 5:1999;3781.
23. Smith V., Sausville E.A., Cavalier R.F., Fiebig H.H., Burger A.M. 17-DMAG (NSC-707545), a water soluble geldanamycin analog, has superior in vitro and in vivo antitumour activity compared to the HSP90 inhibitor, 17 AAG. Eur. J. Cancer. 38(Suppl. 7):2002;. Abs 189.
24. Roe S.M., Prodromou C., O'Brien R., Ladbury J.E., Piper P.W., Pearl L.H. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumour antibiotics radicicol and geldanamycin. J. Med. Chem. 42:1999;260-266.
25. Soga S., Neckers L.M., Schulte T.W., Shiotsu Y., Akasaka K., Narumi H., Agatsuma T., Ikuina Y., Murakata C., Tamaoki T., Akinaga S. KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumour activity via selective depletion of HSP90 binding signalling molecules. Cancer Res. 59:1999;2931-2938.
26. Chiosis G., Timaul M.N., Lucas B., Munster P.N., Zhengg F.F., Sepp-Lorenzino L., Rosen N. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem. Biol. 8:2001;289-299.
27. Chiosis G., Lucas B., Shtil A., Huezo H., Rosen N. Development of a purine - scaffold novel class of HSP90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase. Bioorg. Med. Chem. 10:2002;3555-3564.
28. Aherne G.W., McDonald E., Workman P. Finding the needle in the haystack; why high throughput screening is good for your health. Breast Cancer Res. 4:2002;148-154.
29. Aherne G.W., Garrett M., McDonald E., Workman P. Mechanism-based high-throughput screening for novel anticancer drug discovery. Baguley B.C., Kerr D.J. Anticancer Drug Development. 2002;249-267 Academic Press, San Diego. pp 2.
30. Ali J.A., Jackson A.P., Howells A.J., Maxwell A. The 43-kilodalton N- terminal fragment of the DNA gyrase. β protein hydrolyses ATP and binds coumarin drugs Biochemistry. 32:1993;2717-2724.
31. Lundin A. Use of firefly luciferase in ATP related assays of biomass, enzymes and metabolites. Ziegler M.M., Baldwin T.O. Methods in Enzymology. Vol. 305:2000;346-370 Academic Press.
32. Brune M., Hunter J.L., Corrie J.E.T., Webb M.R. Direct real-time measurement of rapid inorganic phosphate release using a novel fluorescent probe and its application to actinomysin subfragment 1 ATPase. Biochemistry. 33:1994;8262-8271.
33. Brune M., Hunter J.L., Howell S.A., Martin S.R., Hazlett T.C., Corrie J.E.T., Webb M.R. Mechanism of inorganic phosphate interaction with phosphate binding protein from Escherichia coli. Biochemistry. 37:1998;10370-10380.
34. Baykov A.A., Evtushenko O.A., Avaeva S.M. A malachite green procedure for orthophosphate determination and its use in alkaline phosphatase-based enzyme immunoassay. Anal. Biochem. 171:1988;266-270.
35. Harder K.W., Owen P., Wong L.K.H., Aebersold R., Clark-Lewis I., Jirik F.R. Characterization and kinetic analysis of the intracellular domain of human protein tyrosine phosphatase. β (HPTP β ) using synthetic phosphopeptides Biochem. J. 298:1994;395-401.
36. Maehama T., Taylor G.S., Slama J.T., Dixon J.E. A sensitive assay for phosphoinositide phosphatases. Anal. Biochem. 279:2000;248-250.
37. Zhang J.H., Cheung T.D., Oldenburg K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4:1999;67-73.
38. Lanzetta P.H., Alvarez L.J., Reinach P.S., Candia O.A. An improved assay for nanomole amounts of inorganic phosphate. Anal. Biochem. 100:1979;95-97.
39. Aherne G.W., Hardcastle A., Boxall K., Richards J., Tomlin P., Sharp S., Malony A., Workman P. Induction of Hsp70 and depletion of the client protein c-raf-1 measured by ELISA following cellular exposure to the novel Hsp90 ATPase inhibitor, CCT018159. Proc. Am. Assoc. Cancer Res. 44(2nd Ed):2003;. 780, 151.
40. McLaughlin S.H., Smith H.W., Jackson S.E. Stimulation of the weak ATPase activity of human Hsp90 by a client protein. J. Mol. Biol. 315:2002;787-798.
41. Henkel R.D., Vandeberg J.L., Walsh R.A. A microassay for ATPase. Anal. Biochem. 169:1998;312-318.
42. Rumsfeld J., Ziegelbauer K., Spaltmann F. High throughput assay for inorganic pyrophosphatases using the cytosolic enzymes of Saccharomyces cerevisia and human as an example. Protein Exp. Purif. 18:2000;303-309.
43. Lavery P., Brown M.J.B., Pope A.J. Simple absorbance based assays for ultra-high throughput screening. J. Biomol. Screen. 6:2001;3-9.
44. Weikl T., Muschler P., Richter K., Veit T., Reinstein J., Buchner J. C-terminal regions of HSP90 are important for trapping the nucleotide during the ATPase cycle. J. Mol. Biol. 303:2000;583-592.
45. Young J.C., Hartl F.U. Polypeptide release by HSP90 involves ATP hydrolysis and is enhanced by the co-chaperone p23. EMBO J. 19:2000;5930-5940.
46. Obermann W.M.J., Sondermann H., Russo A.A., Parletich N.P., Hartl F.U. In vivo function of HSP90 is dependent on ATP binding and ATP hydrolysis. J. Cell Biol. 143:1998;901-910.